What tirzepatide costs when you're paying cash — compounded, LillyDirect self-pay, and retail — plus the practical ways to bring the number down.
Paying out of pocket, you have three realistic routes. Compounded is the lowest predictable cost; brand-name self-pay is higher but FDA-approved.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Editor's pick | Compounded cash-pay | $186/mo* | Not FDA-approved |
| Other compounded programs | Compounded cash-pay | $209–$400/mo | Not FDA-approved |
| Zepbound® LillyDirect Self Pay | Brand cash-pay | $299–$449/mo | FDA-approved |
| Mounjaro® retail + GoodRx | Brand cash-pay | $900–$1,060/mo | FDA-approved |
| Brand retail, no discount | Brand cash-pay | ~$1,086/mo | FDA-approved |
Many cash-pay compounded programs accept HSA/FSA. See also how to access tirzepatide without insurance (access guide) and cheapest options.
Choose flat-rate compounded pricing so titration doesn't raise your bill; use HSA/FSA dollars; pick a longer plan term for a lower per-month rate; and for brand-name, stay inside the LillyDirect 45-day refill window to hold the $449 maintenance price. Weigh price against clinical oversight and pharmacy transparency rather than choosing on price alone.
Flat-rate compounded programs offered the lowest predictable cash cost; the lowest advertised flat rate in our comparison was about $125/month (annual plan), while our editor's pick on value, NexLife, is $186/month flat. Compounded tirzepatide is not FDA-approved. See NexLife pricing
Cash-pay compounded programs are commonly HSA/FSA-eligible; confirm with your administrator.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.